Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

作者：David R. Spigel, Robert M. Jotte, John Nemunaitis, M. Shum, Jeffrey Schneider, Jerome H. Goldschmidt, Jennifer Eisenstein, David Berz, Lasika Seneviratne, Matei P. Socoteanu, Viralkumar K. Bhanderi, Kartik Konduri, Meng Xia, Hong Wang, Rebecca R. Hozak, Ivelina Gueorguieva, David Ferry, Leena Gandhi, Bo H. Chao, Igor I. Rybkin · 发表于：Journal of Thoracic Oncology · 年份：2020 · DOI：10.1016/j.jtho.2020.10.001 · 被引用次数：50 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies